Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.
| Revenue (Most Recent Fiscal Year) | $3.55M |
| Net Income (Most Recent Fiscal Year) | $-187.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.78 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 6.78% |
| Net Margin (Trailing 12 Months) | 1.96% |
| Return on Equity (Trailing 12 Months) | 0.75% |
| Return on Assets (Trailing 12 Months) | 0.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 19.29 |
| Quick Ratio (Most Recent Fiscal Quarter) | 19.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | $3.62 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 40.62M |
| Free Float | 32.25M |
| Market Capitalization | $569.43M |
| Average Volume (Last 20 Days) | 0.70M |
| Beta (Past 60 Months) | 1.32 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 71.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |